Media headlines about Stryker (NYSE:SYK) have trended somewhat positive recently, Accern reports. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Stryker earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned media stories about the medical technology company an impact score of 46.5583866175071 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
- Electric Operating Table Market Global Overview 2018- Stryker, Eschmann, Trumpf Medical and Berchtold (businessservices24.com)
- Stryker Co. (SYK) Expected to Announce Earnings of $1.60 Per Share (americanbankingnews.com)
- Stryker’s (SYK) “Buy” Rating Reiterated at Guggenheim (americanbankingnews.com)
- Global Medical Electrodes Market 2018 – 3M, Ambu Covid, B. Braun, Stryker (publicsector24.com)
- Global Emergency Medical Service (EMS) Products Market 2018 – Stryker Corporation, Smith & Nephew, Cardinal … (nwctrail.com)
Several analysts have recently weighed in on the stock. Needham & Company LLC restated a “hold” rating on shares of Stryker in a research report on Wednesday, January 31st. Piper Jaffray reaffirmed a “buy” rating and issued a $170.00 target price on shares of Stryker in a report on Wednesday, January 31st. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $163.00 target price on shares of Stryker in a report on Tuesday, January 30th. Guggenheim reaffirmed a “buy” rating on shares of Stryker in a report on Wednesday, January 31st. Finally, Leerink Swann lifted their target price on shares of Stryker from $177.00 to $184.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and sixteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $164.76.
Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.95 by $0.01. Stryker had a net margin of 8.20% and a return on equity of 24.56%. The business had revenue of $3.47 billion for the quarter, compared to analysts’ expectations of $3.42 billion. During the same period in the prior year, the company posted $1.78 EPS. The business’s revenue for the quarter was up 9.9% on a year-over-year basis. sell-side analysts anticipate that Stryker will post 7.12 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Monday, April 30th. Stockholders of record on Thursday, March 29th will be paid a dividend of $0.47 per share. The ex-dividend date is Wednesday, March 28th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.17%. Stryker’s dividend payout ratio (DPR) is presently 70.15%.
In other news, VP Yin C. Becker sold 3,848 shares of the company’s stock in a transaction on Thursday, March 22nd. The shares were sold at an average price of $162.90, for a total transaction of $626,839.20. Following the transaction, the vice president now directly owns 14,641 shares of the company’s stock, valued at approximately $2,385,018.90. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider David Floyd sold 55,119 shares of the company’s stock in a transaction on Thursday, March 15th. The stock was sold at an average price of $166.58, for a total transaction of $9,181,723.02. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 142,386 shares of company stock worth $23,472,005. Corporate insiders own 7.40% of the company’s stock.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.